ArticleGynecologic oncology reports2025
A pilot study investigating the effect of pembrolizumab on the tumoral immunoprofile of newly diagnosed mullerian cancers.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This pilot window of opportunity study was conducted to assess feasibility, toxicity, and changes in immune parameters in response to one dose of the PD-1 inhibitor, pembrolizumab, in patients newly diagnosed with mullerian epithelial cancers. Methods: Eligible patients received pembrolizumab 200 mg IV once ≥ 7 days prior to further standard therapy, including adjuvant chemotherapy. Tissue and blood were collected before and ≥ 7 days after pembrolizumab administration. Primary endpoints included change in tumor infiltrating lymphocytes (TIL), feasibility, and toxicity based on frequency and severity of adverse events. Exploratory objectives included tumor assessment of immunohistochemical PD-L1 staining using a quantitative modified proportion score and qualitative assessment of immune presence at the stromal interface. Measurement of cytokine levels and digital spatial profiling were performed from plasma and tissue samples, respectively, before and after pembrolizumab. Results: Fifteen patients enrolled and received pembrolizumab. TIL levels changed in 4 of 11 paired sets, with 3 decreasing and 1 increasing post-treatment. PD-L1 modified proportion score increased in 7 cases, decreased in 2, and remained unchanged in 2. The stromal interface switched from negative to positive in 3 cases. Collectively, 8 of 10 assessable tumor pairs demonstrated either an increase in PD-L1 modified proportion score or the stromal interface switched from negative to positive. Circulating CXCL10 and TNFα levels increased after pembrolizumab in patients with response, but decreased in the one patient with progression on adjuvant chemotherapy. Digital spatial profiling showed increased IDO1 protein expression in immune and tumor compartments after treatment. Conclusion: A single dose of pembrolizumab increased PD-L1 modified proportion score and/or stromal interface immune cells suggesting potential for local tumor immunologic recruitment. Additionally, increases in systemic inflammation, measured by cytokine production and differential IDO1 expression, reflect an interferon response. These hypothesis-generating data need to be confirmed and validated in larger subsets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.